Xenon Pharmaceuticals Inc (XENE) Stock Price

XENEStock

$59.99+55.41%52W

Market Cap$5.81B

P/E—

PEG Ratio—

Div yield—

Beta0.55

XENE Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)22.01%

Price vs S&P 500 (4W)-5.19%

VGM Score31.23

Book Value / Share (Quarterly)$12.84

P/TBV (Annual)2.63x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-7.35%

Cash Flow / Share (Quarterly)$-3.50

Price vs S&P 500 (YTD)21.03%

Net Profit Margin (TTM)-867.29%

EPS (TTM)$-4.74

10-Day Avg Trading Volume0.71M

EPS Excl Extra (TTM)$-4.74

Revenue Growth (5Y)-25.27%

EPS (Annual)$-4.36

ROI (Annual)-59.46%

Net Profit Margin (5Y Avg)-1413.62%

Cash / Share (Quarterly)$9.62

ROA (Last FY)-54.63%

EBITD / Share (TTM)$-5.07

ROE (5Y Avg)-28.38%

Operating Margin (TTM)-969.84%

Cash Flow / Share (Annual)$-3.50

P/B Ratio5.00x

P/B Ratio (Quarterly)4.70x

Net Income / Employee (Annual)$-966,200

EV / Revenue (TTM)811.91x

Net Interest Coverage (TTM)-38.23x

ROA (TTM)-41.72%

EPS Incl Extra (Annual)$-4.36

Current Ratio (Annual)13.42x

Quick Ratio (Quarterly)20.71x

3-Month Avg Trading Volume1.19M

52-Week Price Return55.41%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$9.79

P/S Ratio (Annual)827.84x

Asset Turnover (Annual)0.01x

52-Week High$72.66

Operating Margin (5Y Avg)-1499.88%

EPS Excl Extra (Annual)$-4.36

CapEx CAGR (5Y)-21.26%

Tangible BV CAGR (5Y)82.20%

26-Week Price Return33.94%

Quick Ratio (Annual)13.17x

13-Week Price Return9.49%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)21.02x

Enterprise Value$6.09B

Revenue / Share Growth (5Y)-36.71%

Asset Turnover (TTM)0.01x

Book Value / Share Growth (5Y)8.23%

Revenue / Employee (Annual)$20,900

Pretax Margin (Annual)-4598.59%

Cash / Share (Annual)$6.86

3-Month Return Std Dev39.26%

Net Income / Employee (TTM)$-1,143,000

ROE (Last FY)-59.46%

Net Interest Coverage (Annual)-22.77x

EPS Basic Excl Extra (Annual)$-4.36

Receivables Turnover (TTM)0.00x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-4.74

Receivables Turnover (Annual)5.28x

ROI (TTM)-43.98%

P/S Ratio (TTM)827.84x

Pretax Margin (5Y Avg)-1410.90%

Revenue / Share (Annual)$0.09

Tangible BV / Share (Annual)$11.53

Price vs S&P 500 (52W)36.86%

Year-to-Date Return33.85%

5-Day Price Return-0.94%

EPS Normalized (Annual)$-4.36

ROA (5Y Avg)-26.66%

Net Profit Margin (Annual)-4612.13%

Month-to-Date Return-4.28%

Cash Flow / Share (TTM)$-2.61

EBITD / Share (Annual)$-4.68

Operating Margin (Annual)-4974.27%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-28.38%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-4.74

P/TBV (Quarterly)2.98x

P/B Ratio (Annual)6.09x

Pretax Margin (TTM)-861.60%

Book Value / Share (Annual)$7.27

Price vs S&P 500 (13W)7.54%

Beta0.55x

P/FCF (Annual)137.85x

Revenue / Share (TTM)$0.00

ROE (TTM)-43.98%

52-Week Low$35.60

vGradeF

gGradeF

mGradeB

vgmGradeD

XENE Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 6, 2026	-$1.16	-$1.11	+4.41%(+$0.05)
Q1 2026	May 7, 2026	-$1.20	-$1.17	+2.29%(+$0.03)
Q4 2025	Feb 26, 2026	-$1.21	-$1.31	-8.67%(-$0.10)
Q3 2025	Nov 3, 2025	-$1.16	-$1.15	+1.23%(+$0.01)
Q2 2025	Aug 11, 2025	-$0.99	-$1.07	-8.45%(-$0.08)

XENE Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.38

Industry Peers — Pharmaceuticals(570)

Symbol	Value Score	Growth Score	Momentum Score	Price
XENEXenon Pharmaceuticals Inc	F	F	B	$59.99
LLYEli Lilly & Co.	D	B	C	$1174.61
JNJJohnson & Johnson	D	C	B	$268.04
ABBVABBVIE INC.	D	C	B	$255.48
MRKMerck & Co., Inc.	D	C	B	$148.35
NVSNovartis AG	C	C	C	$153.81
AZNAstraZeneca PLC	C	B	C	$162.70
NVONovo-Nordisk A/S	B	C	C	$45.61
ABTAbbott Laboratories	C	C	C	$112.47
PFEPfizer Inc.	C	D	B	$27.96
VRTXVertex Pharmaceuticals Inc	D	C	B	$541.69
BMYBristol-Myers Squibb Co.	B	B	B	$66.58
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$44.82
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$50.82
REGNRegeneron Pharmaceuticals Inc	C	C	B	$794.19
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	B	$18.03
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$36.44
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	$366.73
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$60.85
ZTSZOETIS INC.	C	C	D	$77.34
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$237.10
INSMInsmed, Inc.	F	A	C	$118.54
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$34.71
UTHRUnited Therapeutics Corp	C	C	B	$515.46
GMABGenmab A/S ADS	C	C	B	$33.23
VTRSViatris Inc. Common Stock	B	C	B	$16.34
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$247.91
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$244.54
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$76.60
BMRNBioMarin Pharmaceuticals Inc	C	C	B	$64.67
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	B	$533.76
CORTCorcept Therapeutics Inc.	F	C	B	$113.88
ELANElanco Animal Health Incorporated Common Stock	C	B	C	$24.11
ARWRArrowhead Research Corporation	D	A	B	$84.91
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.73
AXSMAxsome Therapeutics, Inc	D	B	C	$199.02
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.18
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$61.05
CYTKCytokinetics Inc.	F	D	C	$72.09
ABVXAbivax SA American Depositary Shares	—	—	C	$113.35
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$344.75
PTGXProtagonist Therapeutics, Inc	F	B	B	$144.33
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.84
TGTXTG Therapeutics, Inc.	D	B	B	$53.93
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	$90.36
ALKSAlkermes Inc. plc	D	C	B	$47.41
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$107.17
ERASErasca, Inc. Common Stock	—	—	A	$18.03
TVTXTravere Therapeutics, Inc. Common Stock	F	B	A	$65.67
BLTEBelite Bio, Inc American Depositary Shares	—	—	C	$151.72

About Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals is a biopharmaceutical company developing novel treatments for neurological and psychiatric disorders, including epilepsy, depression, and pain. The company's pipeline includes three epilepsy candidates—XEN1101, NBI-921352, and XEN496—as well as oral Nav1.7 inhibitors for pain management. It targets areas with significant unmet medical need in neuroscience.